downloadCannabics Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and production of proprietary technologies for treating a wide range of indications through medical cannabis.

The flagship product of Cannabics is the Cannabics SR capsule, a sustained release capsule that provides palliative care to patients suffering from certain types of cancer. The Cannabics SR capsule uses a patented formulation and contains cannabinoids pure concentrate. Cannabinoids are extracted from various strains of the cannabis plant selected and bred by the company. Each capsule provides 10 to 12 hours of therapeutic effects, which allows for once-per-day dosage.

Cannabics Pharmaceuticals, Inc. also supplies other products in the company line, including the condensed Cannabis VP pill for standard vaporizers, and the capsule Cannabics IN for dry powder inhalers. As of 2013, the products of the company have circulated through five hospitals in Israel, where medical marijuana use is permitted for cancer patients and for treatment for pain-related illnesses.

Cannabics Pharmaceuticals, Inc., through its research and development extension in Israel, is developing a pipeline of advanced cannabinoid-based therapies. With the company’s collaboration with major medical centers in the U.S., Israel, and Europe, Cannabics is now launching clinical studies investigating the beneficial effects of their products in a wide range of medical indications.

Cannabics Pharmaceuticals, Inc. is a subsidiary of Cannabics, Inc., and was founded in 2012 by research experts in the fields of molecular biology, cancer research, and pharmacology.  The company, which is based in Bethseda, Maryland, was known as Thrust Energy Corp until 2011, and as American Mining Corporation until June in 2014.

Cannabics Pharmaceuticals, Inc. is traded in the OTC Markets under the stock symbol CNBX. The company’s key executives are Dr. Zohar Koren, CEO and Co-founder; Dr. Eyal Ballan, CTO and Co-founder; and Itamar Borochov, Marketing VP.


Yahoo! Finance: CNBX News

Latest Financial News for CNBX

Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Dana Ben-Ami Shor to its Scientific Board of Advisors.

Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has initiated activities to penetrate European markets in order to offer a test based on its diagnostic platform to patients who suffer from cancer and are treated with cannabinoids, where regulations permit it.

Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Erez Scapa to its Scientific Board of Advisors.

Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with Cannomed Medical Cannabis Industries Ltd. (TASE: CNMD), to develop cannabis cultivars targeted to treat cancers of different types.

Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the Israeli government has granted final approval for the export of medical cannabis and products into international regulated markets such as the European Union (EU), Canada and Australia.